Predicting EGFR T790M Mutation in Brain Metastases Using Multisequence MRI-Based Radiomics Signature

Published:December 30, 2022DOI:

      Rationale and Objectives

      Timely identifying T790M mutation for non-small cell lung cancer (NSCLC) patients with brain metastases (BM) is essential to adjust targeted treatment strategies. To develop and validate radiomics models based on multisequence MRI for differentiating patients with T790M resistance from no T790M mutation in BM and explore the optimal sequence for prediction.

      Materials and Methods

      This retrospective study enrolled 233 patients with proven of BM in NSCLC which included 95 with T790M and 138 without T790M from two hospitals as the training cohort and testing cohort separately. Radiomics features extracted from T2WI, T2 fluid-attenuated inversion recovery (T2-FLAIR), diffusion weighted imaging (DWI) and contrast-enhanced T1-weighted imaging (T1-CE) sequence respectively. The most predictable features were selected based on the maximal information coefficient and Boruta method. Then four radiomics models were built to characterize T790M mutation by random forest classifier. ROC curves, F1 score and DCA curves were constructed to validate the capability and verify the performance of four models.


      The DWI model showed best performance with AUC and F1 score of 0.886 and 0.789 in the training cohort, 0.850 and 0.743 in the testing cohort. DCA curves also showed higher overall net benefit from the DWI model than from the remaining three models in the testing cohort. Other three models also had some classification power whether in the training or testing cohort, especially T2-FLAIR model.


      Multisequence MRI-based radiomics has potential to predict the emergence of EGFR T790M resistance mutations especially the radiomics signature based on DWI sequence.

      Key Words


      AUC (Area under the ROC curve), BM (Brain metastases), ctDNA (Circulating tumor DNA), CNS (Central nervous system), DCA (Decision curve analysis), DWI (Diffusion weighted imaging), EGFR (Epidermal growth factor receptor), GLCM (Gray level co-occurrence matrix), GLRLM (Gray level run length matrix), GLSZM (Gray level size zone matrix), GLDM (Gray level dependence matrix), LC (Lung cancer), MRI (Magnetic resonance imaging), MIC (Maximal information coefficient), NSCLC (Non-small cell lung cancer), NGTDM (Neighbouring gray tone difference matrix), RFC (Random forest classifier), ROI (Region of interest), ROC (Receiver operator characteristic curve), TKIs (Tyrosine kinase inhibitors), T1-CE (Contrast-enhanced T1-weighted imaging), T2-FLAIR (T2 fluid-attenuated inversion recovery), TI (Inversion time)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Academic Radiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Imyanitov EN
        • Iyevleva AG
        • Levchenko EV.
        Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives.
        Crit Rev Oncol Hematol. 2021; 157103194
        • Zhang SS
        • Ou SI.
        Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, "uncommon-G719X, S768I, L861Q") Among the Third-Generation EGFR TKIs?.
        Lung Cancer (Auckl). 2022; 13: 67-73
        • Günther M
        • Juchum M
        • Kelter G
        • et al.
        Lung cancer: EGFR inhibitors with low nanomolar activity against a therapy-resistant L858R/T790M/C797S Mutant.
        Angew Chem Int Ed Engl. 2016; 55: 10890-10894
        • Hou D
        • Li W
        • Wang S
        • et al.
        Different clinicopathologic and computed tomography imaging characteristics of primary and acquired EGFR T790M mutations in patients with non-small-cell lung cancer.
        Cancer Manag Res. 2021; 13: 6389-6401
        • Matzenauer M
        • Vrana D
        • Melichar B.
        Treatment of brain metastases.
        Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016; 160: 484-490
        • Ho HL
        • Wang FY
        • Chiang CL
        • et al.
        Dynamic assessment of tissue and plasma EGFR-Activating and T790M mutations with droplet digital PCR assays for monitoring response and resistance in non-small cell lung cancers treated with EGFR-TKIs.
        Int J Mol Sci. 2022; 23: 11353
        • Rios Velazquez E
        • Parmar C
        • Liu Y
        • et al.
        Somatic mutations drive distinct imaging phenotypes in lung cancer.
        Cancer Res. 2017; 77: 3922-3930
        • Derks SHAE
        • van der Veldt AAM
        • Smits M.
        Brain metastases: the role of clinical imaging.
        Br J Radiol. 2022; 9520210944
        • Binczyk F
        • Prazuch W
        • Bozek P
        • et al.
        Radiomics and artificial intelligence in lung cancer screening.
        Transl Lung Cancer Res. 2021; 10: 1186-1199
        • Jung WS
        • Park CH
        • Hong CK
        • et al.
        Diffusion-weighted imaging of brain metastasis from lung cancer: correlation of MRI parameters with the histologic type and gene mutation status.
        AJNR Am J Neuroradiol. 2018; 39: 273-279
        • Fan Y
        • Dong Y
        • Wang H
        • et al.
        Development and externally validate MRI-based nomogram to assess EGFR and T790M mutations in patients with metastatic lung adenocarcinoma.
        Eur Radiol. 2022; 32: 6739-6751
        • Lee DG
        • Lindsay A
        • Yu A
        • et al.
        Data-driven prediction of fatigue in Parkinson's disease patients.
        Front Artif Intell. 2021; 4678678
        • Yang X
        • Fang C
        • Li C
        • et al.
        Can CT radiomics detect acquired T790M mutation and predict prognosis in advanced lung adenocarcinoma with progression after first- or second-generation EGFR TKIs?.
        Front Oncol. 2022; 12904983
        • He R
        • Yang X
        • Li T
        • et al.
        A machine learning-based predictive model of epidermal growth factor mutations in lung adenocarcinomas.
        Cancers (Basel). 2022; 14: 4664
        • Perez-Johnston R
        • Araujo-Filho JA
        • Connolly JG
        • et al.
        CT-based radiogenomic analysis of clinical stage I lung adenocarcinoma with histopathologic features and oncologic outcomes.
        Radiology. 2022; 303: 664-672
        • Jia TY
        • Xiong JF
        • Li XY
        • et al.
        Identifying EGFR mutations in lung adenocarcinoma by noninvasive imaging using radiomics features and random forest modeling.
        Eur Radiol. 2019; 29: 4742-4750
        • Li Y
        • Lv X
        • Wang B
        • et al.
        Differentiating EGFR from ALK mutation status using radiomics signature based on MR sequences of brain metastasis.
        Eur J Radiol. 2022; 155110499
        • Wang G
        • Wang B
        • Wang Z
        • et al.
        Radiomics signature of brain metastasis: prediction of EGFR mutation status.
        Eur Radiol. 2021; 31: 4538-4547
        • Jiang X
        • Ren M
        • Shuang X
        • et al.
        Multiparametric MRI-based radiomics approaches for preoperative prediction of EGFR mutation status in spinal bone metastases in patients with lung adenocarcinoma.
        J Magn Reson Imaging. 2021; 54: 497-507
        • Chen BT
        • Jin T
        • Ye N
        • et al.
        Radiomic prediction of mutation status based on MR imaging of lung cancer brain metastases.
        Magn Reson Imaging. 2020; 69: 49-56
        • Takeda M
        • Okamoto I
        • Nakagawa K.
        Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with Gefitinib or Erlotinib.
        J Thorac Oncol. 2014; 9: 200-204
        • Wang ZF
        • Ren SX
        • Li W
        • et al.
        Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis.
        BMC Cancer. 2018; 18: 148
        • Yi XF
        • Song J
        • Gao RL
        • et al.
        Efficacy of Osimertinib in EGFR-mutated advanced non-small-cell lung cancer with different T790M status following resistance to prior EGFR-TKIs: a systematic review and meta-analysis.
        Front Oncol. 2022; 12863666
        • Remon J
        • Steuer CE
        • Ramalingam SS
        • et al.
        Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients.
        Ann Oncol. 2018; 29 (suppl_): i20-i27
        • Fan Y
        • He L
        • Yang H
        • et al.
        Preoperative MRI-based radiomics of brain metastasis to assess T790M resistance mutation after EGFR-TKI treatment in NSCLC.
        J Magn Reson Imaging. 2022;
        • Kawamura T
        • Kenmotsu H
        • Omori S
        • et al.
        Clinical factors predicting detection of T790M Mutation in rebiopsy for EGFR-mutant non-small-cell lung cancer.
        Clin Lung Cancer. 2018; 19: e247-e252